Skip to main content

Merendino Lauren's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Nov 18, 2025

Accession no.
0001855298-25-000007
Filed
Nov 18, 2025
Trade date
Nov 15-17, 2025
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $33.2K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Merendino LaurenCIK 0001855298Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2025Common StockMOption exerciseAcquired+3,162––47,161Direct
Nov 15, 2025Common StockMOption exerciseAcquired+3,687––50,848Direct
Nov 15, 2025Common StockMOption exerciseAcquired+3,687––54,535Direct
Nov 17, 2025Common StockSSaleDisposed−3,726$8.91−$33,198.6650,809Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 15, 2025Common StockMOption exerciseDisposed−3,162$0.00$022,140Direct
Nov 15, 2025Common StockMOption exerciseDisposed−3,687$0.00$029,504Direct
Nov 15, 2025Common StockMOption exerciseDisposed−3,687$0.00$044,252Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)